What is Zacks Small Cap’s Forecast for TELO FY2024 Earnings?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) – Analysts at Zacks Small Cap issued their FY2024 earnings per share estimates for Telomir Pharmaceuticals in a research report issued to clients and investors on Thursday, November 21st. Zacks Small Cap analyst B. Sorensen forecasts that the company will post earnings of ($0.54) per share for the year. Zacks Small Cap also issued estimates for Telomir Pharmaceuticals’ Q4 2024 earnings at ($0.05) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.18) EPS.

Telomir Pharmaceuticals Stock Down 5.1 %

Shares of TELO stock opened at $4.24 on Monday. Telomir Pharmaceuticals has a one year low of $3.11 and a one year high of $20.72. The stock has a fifty day moving average price of $5.03 and a 200 day moving average price of $5.01.

Hedge Funds Weigh In On Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC raised its position in Telomir Pharmaceuticals by 325.1% in the third quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after purchasing an additional 5,367 shares in the last quarter. Beaird Harris Wealth Management LLC increased its stake in shares of Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after buying an additional 9,950 shares in the last quarter. State Street Corp raised its holdings in shares of Telomir Pharmaceuticals by 99.1% in the third quarter. State Street Corp now owns 36,094 shares of the company’s stock valued at $232,000 after buying an additional 17,967 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Telomir Pharmaceuticals in the 2nd quarter valued at about $241,000. Finally, Suncoast Equity Management lifted its position in shares of Telomir Pharmaceuticals by 109.9% during the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock worth $329,000 after purchasing an additional 26,803 shares in the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.